10-Q: Aptevo Therapeutics Reports Q1 2025 Financial Results, Cites Going Concern Uncertainty Amidst Clinical Development

Aptevo Therapeutics reports a net loss of $6.4 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while continuing clinical trials and seeking additional funding.

Summary

• Aptevo Therapeutics Inc. reported a net loss of $6.4 million for the three months ended March 31, 2025, compared to a net loss of $6.8 million for the same period in 2024.
• The company's accumulated deficit as of March 31, 2025, was $254.0 million.
• Net cash used in operating activities was $6.6 million for the three months ended March 31, 2025.
• Aptevo expresses substantial doubt about its ability to continue as a going concern for the one-year period from the date of issuance of these financial statements.
• The company is focused on developing novel immunotherapy candidates for cancer treatment, with two clinical candidates (mipletamig and ALG.APV-527) and three preclinical candidates in development.
• Aptevo is conducting a Phase 1b/2 clinical trial for mipletamig in combination with venetoclax and azacitidine for frontline acute myelogenous leukemia (AML).
• Enrollment continues in the RAINIER dose optimization trial, with Cohort 2 complete and Cohort 3 enrolling.
• Aptevo is also evaluating ALG.APV-527 for the treatment of multiple solid tumor types in a dose escalation trial.
• The company completed registered direct offerings in April 2025, raising $3.7 million in proceeds.
• Aptevo entered into an At The Market Offering Agreement in April 2025 to sell shares of common stock for up to $50 million.
• Stockholders approved a proposal to amend the exercise price of December 2024 Common Warrants to $1.19 per share on May 14, 2025.
• The company may receive up to an additional $6.8 million in gross proceeds if outstanding common warrants are exercised.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive clinical trial results, the financial situation and going concern warning weigh heavily on the overall sentiment.

Positives

• 90% of frontline AML patients across two trials have achieved remission with mipletamig in combination with standard of care therapy.
• No cytokine release syndrome (CRS) has been observed in the ongoing RAINIER trial to date.
• The company completed registered direct offerings in April 2025, raising $3.7 million in proceeds.
• Aptevo entered into an At The Market Offering Agreement in April 2025 to sell shares of common stock for up to $50 million.
• Stockholders approved a proposal to amend the exercise price of December 2024 Common Warrants to $1.19 per share on May 14, 2025.
• The company may receive up to an additional $6.8 million in gross proceeds if outstanding common warrants are exercised.

Negatives

• Aptevo Therapeutics reported a net loss of $6.4 million for Q1 2025 and an accumulated deficit of $254.0 million.
• The company expresses substantial doubt about its ability to continue as a going concern.
• The company has suffered recurring losses from operations and negative cash flows from operating activities.
• The company will require substantial additional funds to continue its development programs and to fulfill its planned operating goals.

Risks

• Aptevo expresses substantial doubt about its ability to continue as a going concern.
• The company's future success depends on its ability to develop and commercialize product candidates, which is subject to significant uncertainty.
• Aptevo faces intense competition and may not be able to effectively compete.
• The company's business is affected by macroeconomic conditions, including rising and fluctuating inflation, market volatility, and supply chain constraints.
• Aptevo may not be successful in its efforts to use and further develop its ADAPTIR or ADAPTIR-FLEX platforms.
• If Aptevo is unable to protect its intellectual proprietary rights, its business could be harmed.
• The results of preclinical studies and clinical trials may not satisfy regulatory requirements.
• Serious adverse events or undesirable side effects of product candidates may delay or prevent regulatory approval.
• Aptevo depends on third parties to conduct clinical and non-clinical trials, and their failure to perform effectively could harm the business.
• Aptevo's stock price is and may continue to be volatile.
• The company may be subject to periodic litigation, which could result in losses or unexpected expenditure of time and resources.
• Aptevo's common stock may be at risk for delisting from the Nasdaq Capital Market if it does not maintain compliance with Nasdaq's continued listing requirements.

Future Outlook

Aptevo anticipates continuing to incur significant operating losses for the next several years as it continues to execute on its development strategy to advance its preclinical and clinical stage assets. The company will require substantial additional funds to continue its development programs and to fulfill its planned operating goals.

Management Comments

• Management and board of directors have concluded that a substantial doubt is deemed to exist concerning our ability to continue as a going concern.

Industry Context

Aptevo operates in the highly competitive biotechnology industry, focusing on developing novel immunotherapy candidates for cancer treatment. The company faces competition from established pharmaceutical companies and other biotechnology firms, including AbbVie Inc., Amgen Inc., Bristol Myers Squibb, and Novartis, among others. The success of Aptevo's product candidates depends on their ability to demonstrate superior efficacy, safety, and cost-effectiveness compared to existing treatments and those in development by competitors.

Comparison to Industry Standards

• Aptevo's Q1 2025 net loss of $6.4 million is within the range of losses reported by other clinical-stage biotechnology companies of similar size.
• However, the company's expression of substantial doubt about its ability to continue as a going concern is a significant concern and distinguishes it from many of its peers.
• Companies like MacroGenics and Xencor, which also focus on antibody-based therapeutics, have achieved greater clinical and commercial success, providing a benchmark for Aptevo's future performance.
• Aptevo's reliance on external funding and collaborations is common in the industry, but its ability to secure these resources will be critical for its long-term viability.
• The clinical data from Aptevo's mipletamig trial, with 90% of frontline AML patients achieving remission, is promising but needs to be validated in larger, controlled studies to compete with established AML therapies.

Stakeholder Impact

• Shareholders face potential dilution from future equity issuances.
• Employees face uncertainty due to the company's going concern status.
• Patients may benefit from the development of new cancer therapies.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• Continue enrollment in the RAINIER dose optimization trial.
• Advance the clinical development of mipletamig and ALG.APV-527.
• Seek additional funding through public or private financing, collaborative or licensing arrangements, or credit lines.
• Maintain compliance with Nasdaq's continued listing requirements.
• Monitor and manage cash flow to ensure sufficient resources for operations.

Key Dates

Keywords

Aptevo Therapeutics, mipletamig, ALG.APV-527, clinical trials, immunotherapy, cancer, AML, biotechnology, financial results, going concern, warrants, stock offerings, ADAPTIR, ADAPTIR-FLEX